ERBC (ex CERB) has acquired RTC

The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).

ERBC provides healthcare and chemical professionals a comprehensive range of experimental capabilities and services, from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, and also benefiting from a world-class academic and private network.

RTC is a fully fledged contract research laboratory located near Rome, Italy, with a track record spanning more than four decades. RTC collaborates with a large range of industrial clients including the pharmaceutical, biotech, chemical, agro-chemical and biocide industries.

Oaklins' team in France advised the buyer in this transaction.

Service

M&A buy-side

Parties

“With the help of Oaklins, we are thrilled to join forces and offer a critical mass of credible and efficient alternative to the big CROs. We are proud to be a unique European player in the field. Our partnerships with the pharma, other CROs and independent experts play a key role in driving improvements in the pharmaceutical and chemical industries, delivering better data to regulators as well as improved value to study sponsors. Oaklins' team gave us fantastic support in a complex transaction.”

Serge Richard

CEO, ERBC

Talk to the deal team

Thibaut de Monclin

Managing Partner

Paris, France
Oaklins France

View profile Get in touch

Related deals

Bolster Investment Partners has acquired a majority stake in Eternal Sun

Private Equity | Energy

Bolster Investment Partners has acquired a majority stake in Eternal Sun

Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.

Learn more

Cerbios-Pharma has been acquired by HAS Healthcare

Healthcare

Cerbios-Pharma has been acquired by HAS Healthcare

Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.

Learn more

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

Private Equity | Construction & Engineering Services | Energy | TMT

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.

Learn more